Clinical Trial Update: Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating toripalimab as maintenance therapy after first-line chemotherapy in driver-gene negative advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Toripalimab (Toripalimab)

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: NSCLC Stage IV | Phase 2 | Status: UNKNOWN